GSK now owns the global development and commercialisation rights to Empirico's COPD-targeting (siRNA) oligonucleotide, ...

Yesterday, GSK added a new antibody-drug conjugate to its cancer pipeline via a $358 million agreement with French biotech ...

Q3 2025 Earnings Call Transcript October 29, 2025 GSK plc beats earnings expectations. Reported EPS is $1.48, expectations ...

Cash generated from operations totaled £2.5 billion, with free cash flow of £1.2 billion. GSK declared a dividend of 16 pence ...

GSK’s antibody-drug conjugate strategy may be making more headlines recently, but the British pharma hasn’t forgotten about ...

GSK raised its full-year guidance on Wednesday, after delivering stronger-than-expected third-quarter results, driven by ...

Cash generated from operations totaled £2.5 billion, with free cash flow of £1.2 billion. GSK declared a dividend of 16 pence ...

GSK is shelling out $85 million up front, and possibly $745 million overall, for an RNA-based therapy it sees helping a ...

GSK plc GSK reported third-quarter 2025 core earnings of $1.48 per American depositary share (ADS), which beat the Zacks Consensus Estimate of $1.26. Core earnings increased 11% year over year on a ...

GSK (LSE:GSK) has delivered share price gains of 9% over the past month and 16% in the past 3 months, reflecting steady ...

Mepolizumab significantly reduced healthcare resource utilization, including hospitalizations and emergency department visits, in patients with severe eosinophilic asthma over two years. The treatment ...